Stay updated on Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial

Sign up to get notified when there's something new on the Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The study record for the nivolumab and ipilimumab prostate cancer trial is now displayed, including its treatment plan, eligibility criteria, locations, and outcome measures.
    Difference
    47%
    Check dated 2026-11-08T04:47:00.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T02:11:49.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    A notice announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology under Executive Order 14434. It appears above the ClinicalTrials.gov error message.
    Difference
    1%
    Check dated 2026-10-25T02:07:28.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T01:56:42.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision advanced from v3.7.0 to v3.7.1, while the study page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T02:28:58.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    Added a new Revision: v3.7.0 tag and removed a broad list of metadata terms and keywords. This updates how the record is indexed and what topics are associated with it, without changing core study content.
    Difference
    18%
    Check dated 2026-09-20T01:31:05.000Z thumbnail image

Stay in the know with updates to Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial page.